Publications
Detailed Information
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Moehler, Markus | - |
dc.contributor.author | Ryu, Min-Hee | - |
dc.contributor.author | Dvorkin, Mikhail | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Coskun, Hasan S. | - |
dc.contributor.author | Wong, Rachel | - |
dc.contributor.author | Chung, Hyun C. | - |
dc.contributor.author | Poltoratsky, Artem | - |
dc.contributor.author | Tsuji, Akihito | - |
dc.contributor.author | Yen, Chia Jui | - |
dc.contributor.author | Muntean, Alina S. | - |
dc.contributor.author | Le Sourd, Samuel | - |
dc.contributor.author | Vaccaro, Gina M. | - |
dc.contributor.author | Overton, Lindsay | - |
dc.contributor.author | Boku, Narikazu | - |
dc.contributor.author | Wainberg, Zev A. | - |
dc.contributor.author | Patel, Manish | - |
dc.contributor.author | Sharma, Maitreyi | - |
dc.contributor.author | Xiong, Huiling | - |
dc.contributor.author | Conti, Ilaria | - |
dc.contributor.author | Taieb, Julien | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2021-01-31T11:10:04Z | - |
dc.date.available | 2021-01-31T11:10:04Z | - |
dc.date.created | 2019-03-19 | - |
dc.date.issued | 2019-02 | - |
dc.identifier.citation | Future Oncology, Vol.15 No.6, pp.567-577 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.other | 72744 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173073 | - |
dc.description.abstract | Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in early phase studies in advanced/metastatic gastric/gastroesophageal junction cancer, including as first-line maintenance therapy. Here, we describe the design of JAVELIN Gastric 100 (NCT02625610), an open-label, Phase III trial. A total of 499 patients with locally advanced/metastatic HER2- gastric/gastroesophageal junction cancer adenocarcinoma, who had achieved at least stable disease following 12 weeks of first-line oxaliplatin/fluoropyrimidine chemotherapy, have been randomized 1:1 to receive avelumab maintenance therapy or continue chemotherapy. The primary objective is to demonstrate superior overall survival in all randomized patients or in the PD-L1+population. Secondary objectives are to demonstrate superiority for progression-free survival and objective response rate, compare quality of life measures, and determine safety. | - |
dc.language | 영어 | - |
dc.publisher | Future Medicine Ltd. | - |
dc.title | Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.2217/fon-2018-0668 | - |
dc.citation.journaltitle | Future Oncology | - |
dc.identifier.wosid | 000458899100002 | - |
dc.identifier.scopusid | 2-s2.0-85061250794 | - |
dc.citation.endpage | 577 | - |
dc.citation.number | 6 | - |
dc.citation.startpage | 567 | - |
dc.citation.volume | 15 | - |
dc.identifier.sci | 000458899100002 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, Keun-Wook | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | PATHWAYS | - |
dc.subject.keywordAuthor | avelumab | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | PD-L1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.